Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

98.83 -0.47 (-0.47%)
Streaming Delayed Price Updated: 12:32 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
2 Safe-and-Steady Stocks Worth Your Attention and 1 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Monday's session: top gainers and losers in the S&P500 index ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Top S&P500 movers in Monday's session ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Monday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Change to its Board of Directors
From Incyte
Via Business Wire
News headline image
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
From Incyte
Via Business Wire
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
From Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
2 S&P 500 Stocks Worth Investigating and 1 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
From Incyte
Via Business Wire
News headline image
Gapping S&P500 stocks in Monday's session ↗
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Friday's session ↗
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Fits Minervini Trend Template with Strong Growth Momentum ↗
INCYTE stock shows strong technical uptrends per Minervini's Trend Template, backed by accelerating earnings and revenue growth for high momentum. 
Via Chartmill
News headline image
2 Growth Stocks Set to Flourishand 1 Facing Challenges
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
News headline image
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. 
Via StockStory
Topics Economy
News headline image
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Top S&P500 movers in Tuesday's pre-market session ↗
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY) Presents a Compelling Case for Value Investors ↗
INCYTE CORP (INCY) is a strong value investing candidate with a low P/E ratio, a healthy balance sheet, and solid profitability, suggesting it's an undervalued stock. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.